EyeControl Overview
EyeControl is a medical technology company revolutionizing ICU care with its AI-powered eye-tracking platform. Designed to empower mechanically ventilated patients, it enables effective communication, connects families and caregivers, and provides healthcare teams with actionable insights. By supporting implementation of evidence-based practices for optimizing critical care, EyeControl enhances patient safety, improves cognitive and mental health outcomes, and fosters meaningful connections. The EyeControl device is FDA-listed, CE-marked, ISO-certified, and AMAR and MAKAT registered as a communication solution. It is federally reimbursed in Israel for inpatient settings and homecare.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Israeli company EyeControl creates revolutionary medical technology
EyeControl, an Israeli company, has developed a revolutionary medical technology that allows ICU patients to communicate through eye gestures and a bone conduction headset. This technology is proving beneficial in preventing cognitive decline and enhancing patient experiences, particularly for soldiers. The company is conducting clinical trials in Israel and the US, supported by the Israel-US Binational Industrial Research and Development fund and the NIH AI program. Recent investments from the European Bank and Googles AI Fund are aiding its expansion. EyeControls technology is being implemented in hospitals under Clalit in Israel and selected sites in the US. The company aims to reduce ICU delirium and improve patient care globally.
InvestmentPartners
growth-positive
Talking to the unconscious: Israelis reduce delirium during surgery
EyeControl, a startup founded in 2016, has developed a device that aids communication for ICU patients who are unable to speak due to sedation or injury. The device, which uses eye-tracking technology, allows patients to communicate through pre-prepared messages. It has shown promise in reducing ICU delirium and is currently being tested in a large trial involving hospitals like Assuta Ashdod and Beilinson Hospital. The trial is partially funded by the BIRD Fund and NIH, with a budget of $1.8 million. EyeControls technology is seen as a potential game-changer in ICU care, offering both clinical and economic benefits. The company has raised about $10 million and received $8 million in grants, positioning itself for growth in the hospital market.
InvestmentPartners
Growth-Positive
הסטארט-אפ הזה מצא שיטה מפתיעה להפחית הזיות בטיפול נמרץ
Israeli start-up EyeControl has developed a device that allows medical teams and families to communicate with sedated patients, reducing delirium and simultaneously serving as a means for patients to communicate with their eyes. The device, which came into existence in 2016, has become increasingly necessary in intensive care units. Dr. Ami Mayo, director of intensive care at the public hospital Asuta Ashdod, admitted he was surprised when a patient who woke up and became agitated in his department immediately calmed down when the companys device was put on him.
Customers
Israeli med tech company’s innovative headset could reduce delirium in ICU patients
growth-positive
EyeControl פיתחה אביזר אלחוטי המאפשר למונשמים וחולי ALS לתקשר - Techtime - חדשות אלקטרוניקה והייטק
Israeli start-up EyeControl has developed a wireless wearable device that enables patients who struggle to speak due to their medical condition to communicate using only eye movements. The device was originally developed for patients with ALS who have lost their ability to speak. The company has also developed a version for hospital patients, EyeControl-Med. The company is currently completing a clinical study to demonstrate how their communication device can help reduce delirium among hospitalized patients. Preliminary findings from the study suggest that the device reduced the number of errors made by patients in delirium tests and improved communication and interaction with the hospital staff.
InvestmentExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $15.21M |
| Last funding | Undisclosed |
| Stage | A |
| Rounds | 13 |
| Investors | 13 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | www.eyecontrol.co.il |
Locations
Menachem Begin Street 48, Tel Aviv, Israel
Photos & Videos
6 item(s)
